Top
Mucopolysaccharidosis (MPS) IIIB (MPSIIIB) - Healing Genes
1253
post-template-default,single,single-post,postid-1253,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Mucopolysaccharidosis (MPS) IIIB (MPSIIIB)

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB (MPSIIIB)

Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB


Phase 1 / 2

DESCRIPTION:

The Nationwide Children’s Hospital in Columbus, OH, is recruiting patients with Mucopolysaccharidosis (MPS) IIIB (MPSIIIB) for a clinical trial of a gene therapy that will attempt to impart a functional copy of the NAGLU gene. This therapy is a genetically-engineered virus that delivers the gene, and treatment will involve a one-time infusion in addition to a tapering course of steroids. Improved health and cognitive ability are some of the goals of this treatment.

Follow up for 2 years will include lab testing and clinical assessments to track NAGLU enzyme activities and overall health.


PATIENT MUST:

  • Be 6 months of age or older
  • Have a confirmed diagnosis of MPSIIIB by both of the following two methods:
    • No detectable or significantly reduced NAGLU enzyme activity by plasma, serum, or leukocyte assay.
    • Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the NAGLU gene
  • Not have received prior treatment with NAGLU enzyme replacement therapy (ERT)

THE STUDY INVOLVES:

  1. Screening before the treatment, possibly including DNA assessments
  2. A single infusion of the gene therapy drug will be administered at one of two dose levels.
  3. Monitoring of the patient for a few hours after dosing, with lab, physical, and cognitive assessments required for up to 2 years post treatment.

LOCATIONS AND CONTACTS:

Trials will take place at the Nationwide Children’s Hospital in Columbus, OH. Map.

Contacts:
Federica Rinaldi, PhD  |   614-355-2897  |  [email protected]
Tabatha Simmons, PhD  |  614-722-6921  |  [email protected]
 
SPONSOR INFORMATION:
Abeona Therapeutics, Inc
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03315182

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader